News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AREVA Med LLC Selects Goodwin Biotechnology, Inc. as a Partner for Its New Cancer Treatment


5/18/2009 8:32:14 AM

PLANTATION, Fla.--(BUSINESS WIRE)--Goodwin Biotechnology Inc. (GBI) disclosed today that following its recent formation, AREVA Med LLC has decided to extend its collaboration with GBI toward the development of AREVA Med’s lead-212 (212Pb) initiative to treat cancer. The operation previously engaged with AREVA will continue with AREVA Med and will result in the manufacture of a new conjugated drug that will be radiolabeled by the NCI. AREVA Med will benefit from the vast expertise in the nuclear industry from its parent company that allowed for the production of this radioisotope previously considered a scarce resource.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES